ATP 检测市场 - 全球产业规模、份额、趋势、机会及预测（按类型、应用、最终用途、地区和竞争格局划分，2021-2031 年）

全球 ATP 检测市场预计将从 2025 年的 36.3 亿美元成长到 2031 年的 56.9 亿美元，复合年增长率为 7.78%。

此细分市场主要包括利用生物发光技术测量三Adenosine(ATP) 的生化诊断解决方案，ATP 可快速指示细胞活力和微生物污染情况。推动该细分市场成长的主要因素是製药业日益严格的监管要求，例如欧盟 GMP 附录 1，以及食品饮料产业为避免安全事故而对即时卫生检验日益增长的需求。这些关键驱动因素独立于携带式侦测装置与云端资料分析结合的新兴技术变革而发挥作用。

这些卫生通讯协定在高风险环境中的有效性已得到证实，这进一步凸显了此类快速监测设备的必要性。 2024年美国医院协会（AHA）的数据显示，医院中央静脉导管相关血流感染率年减15%，凸显了这些检测方法所支持的严格表面监测的关键作用。儘管取得了这些进展，但市场仍面临一个显着的障碍：标准ATP检测固有的特异性不足。标准ATP检测无法区分微生物残留和有机残留，这使得污染源的识别变得复杂，并限制了其更广泛的应用。

市场驱动因素

生物技术和製药行业研发投入的不断增长正推动资源流向毒性测试和临床前研究，成为全球ATP检测市场的主要驱动力。随着企业投入大量资金开发新型疗法，对可靠的细胞毒性和细胞活力检测的需求也相应增长，而ATP检测因其快速和灵敏的优势而备受青睐。这些投资使得企业能够购买用于药物候选物早期严格评估的先进生物发光试剂和试剂盒。根据美国药品研究与製造商协会（PhRMA）于2024年9月发布的《2024年PhRMA会员调查报告》，会员企业2023年的研发投入将达到创纪录的1035亿美元，这与实验室对代谢监测工具的日益普及直接相关。

同时，癌症和慢性疾病发生率的不断上升正在加速依赖高通量筛检技术的药物研发。尤其是在肿瘤学领域，代谢活性被用于评估癌细胞的健康状况，实验室越来越依赖基于ATP的生物发光技术来评估庞大的化合物库对特定疾病模型的疗效。美国癌症协会于2024年1月发布的《2024年癌症事实与数据》报告预测，当年美国将新增2,001,140例癌症病例，凸显了推动此类筛检的巨大临床需求。这些努力的成功也体现在监管方面的成果中，美国食品药物管理局（FDA）在2024年宣布，前一年已核准了55种新的治疗药物。这显示，药物研发管线十分强大，需要在整个研发过程中持续应用代谢谱分析工具。

市场挑战

全球ATP检测市场面临的主要障碍是标准生物发光检测固有的非特异性。这些检测无法区分有害微生物污染和无害有机残留物。这项技术缺陷显着限制了ATP检测在关键控制领域的应用，而准确识别污染源至关重要。如果检测结果呈阳性，操作人员无法确定ATP水平升高是表示存在有害病原体，还是仅仅表示食品安全。这种不确定性迫使生产者依赖其他更耗时的检测方法，例如聚合酵素链锁反应（PCR），来确认残留物的性质，从而阻碍了ATP检测作为一种全面、独立的诊断工具发挥作用。

这种特异性的缺失严重阻碍了其在敏感领域（例如无过敏原食品生产和製药无尘室）的市场推广。随着消费者对细菌安全性的日益重视，无法提供病原体特异性检验的问题尤其突出。根据国际食品资讯理事会 (IFIC) 2024 年的一项调查，仅有 62% 的消费者对美国食品供应的安全性表示有信心，47% 的消费者将细菌性食源性疾病列为他们最关心的问题。这凸显了市场上的一个缺口：ATP 检测的通用检测能力无法满足细菌检验的特定要求，从而有效地抑制了需要绝对病原体确认的领域的发展。

市场趋势

将ATP检测方法应用于类器官模型和3D细胞培养，代表临床前药物研发领域的重大技术革新，突破了传统单层培养测试的限制。随着製药公司优先考虑生理学上精确的模型以降低后期临床试验的失败率，对能够有效裂解高密度球状体并精确量化其活性的专用ATP试剂的需求激增。大型合约研发生产机构（CDMO）不断扩展其高内涵筛检能力，也印证了这项转变。例如，三星生物製剂公司在2025年12月宣布，已于2025年6月推出专门的类器官服务，旨在提高国际客户临床研究的柔软性和速度，从而策略性地扩展其产品组合。

同时，在医疗设备再处理通讯协定中应用快速ATP检测正在改变医疗机构的卫生合规性。为了应对日益增长的环境和成本压力，医院正在迅速扩大对再处理一次性医疗设备的使用。这种做法需要在灭菌前进行严格的清洁检验，以防止感染传播。这种扩张直接推动了ATP生物发光检测作为关键品管标准的应用。根据医疗设备再处理协会（AMDR）2025年4月的一项研究，到2024年，美国医院透过使用受监管的再处理设备，可节省超过4.51亿美元的成本。这凸显了需要进行标准化清洁度检验的大量库存。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球ATP检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（发光 ATP 检测、酶 ATP 检测、生物发光共振能量转移 (BRET) ATP 检测、基于细胞的 ATP 检测、其他）
  • 按应用领域（药物发现与开发、临床诊断、环境检测、食品安全与品质检测等）
  • 按最终用途（製药和生物技术公司、学术和研究机构、医院和诊断检查室）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美ATP检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲ATP检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区ATP检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲ATP检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美ATP检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球ATP侦测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Promega Corporation
• PerkinElmer Inc.
• Becton, Dickinson and Company（BD）
• Lonza Group AG
• DH Life Sciences, LLC.
• Abcam Limited
• Quest Diagnostics Incorporated
• BIOMeRIEUX SA
• 3M Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global ATP Assays Market is projected to expand from a valuation of USD 3.63 Billion in 2025 to USD 5.69 Billion by 2031, registering a CAGR of 7.78%. This sector comprises biochemical diagnostic solutions that measure Adenosine Triphosphate, largely through bioluminescence, to serve as rapid indicators of cellular viability and microbial contamination. Growth is principally driven by strict regulatory requirements in pharmaceutical production, such as EU GMP Annex 1, alongside an increasing necessity for real-time hygiene verification in the food and beverage sector to avert safety incidents. These core drivers operate independently of the emerging technological shift toward combining handheld testing units with cloud-based data analytics.

The proven effectiveness of these sanitation protocols in high-stakes environments reinforces the need for such rapid monitoring instruments. Data from the American Hospital Association in 2024 indicates that hospitals realized a 15% decrease in central line-associated bloodstream infections compared to the prior year, highlighting the critical role of the rigorous surface monitoring enabled by these assays. Despite this progress, the market encounters a notable obstacle regarding the inherent lack of specificity in standard ATP tests, which fail to distinguish between microbial and organic residues, thereby complicating the identification of contamination sources and limiting wider adoption.

Market Driver

Increasing expenditure on research and development within the biotechnology and pharmaceutical sectors acts as a primary catalyst for the Global ATP Assays Market by boosting resources for toxicity testing and preclinical studies. As corporations commit substantial capital to creating new therapeutics, the requirement for dependable cytotoxicity and cell viability assays rises accordingly, with ATP detection preferred for its speed and sensitivity. This financial investment enables the acquisition of sophisticated bioluminescent reagents and kits necessary for the strict early-phase assessment of drug candidates. According to the '2024 PhRMA Annual Membership Survey' released by the Pharmaceutical Research and Manufacturers of America in September 2024, member companies directed $103.5 billion toward research and development in 2023, a record amount that correlates directly with higher laboratory usage of metabolic monitoring tools.

Concurrently, the growing incidence of cancer and chronic diseases is quickening drug discovery efforts that depend on high-throughput screening techniques. Laboratories rely increasingly on ATP-based bioluminescence to evaluate extensive compound libraries for effectiveness against specific disease models, especially in oncology where tumor cell health is gauged by metabolic activity. The American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024 projects 2,001,140 new cancer cases in the United States for the year, highlighting the critical clinical demand driving this screening. The success of these initiatives is reflected in regulatory achievements; the U.S. Food and Drug Administration noted in 2024 that 55 novel therapeutics were approved the previous year, indicating a strong pipeline that requires the persistent application of metabolic profiling tools throughout development.

Market Challenge

The central obstacle hindering the Global ATP Assays Market is the intrinsic non-specificity associated with standard bioluminescence testing, which fails to distinguish between hazardous microbial contamination and benign organic residues. This technical shortcoming significantly limits the application of ATP assays in critical control settings where accurate identification of contamination sources is mandatory. When a test result is positive, operators are unable to determine if the elevated ATP readings signify the presence of harmful pathogens or merely safe food byproducts. This uncertainty frequently compels manufacturers to rely on additional, slower testing methods like Polymerase Chain Reaction (PCR) to verify the residue's nature, preventing ATP assays from serving as a comprehensive standalone diagnostic tool.

As a result, this lack of specificity presents a major hurdle to market adoption in sensitive sectors such as allergen-free food manufacturing and pharmaceutical cleanrooms. The inability to offer pathogen-specific validation is especially damaging given the growing consumer emphasis on bacterial safety. According to the International Food Information Council in 2024, only 62% of consumers reported confidence in the safety of the U.S. food supply, with 47% identifying foodborne illness caused by bacteria as their primary worry. This evidence highlights a gap in the market where the general detection capacity of ATP assays falls short of the specific requirement for bacterial verification, effectively impeding growth in segments that demand absolute confirmation of pathogens.

Market Trends

Incorporating ATP assays into organoid models and 3D cell cultures marks a significant technical evolution in preclinical drug development, advancing beyond the constraints of conventional monolayer testing. As pharmaceutical firms prioritize physiologically accurate models to decrease late-stage clinical attrition, there is a surging demand for specialized ATP reagents designed to effectively lyse dense spheroids for precise viability quantification. This shift is further illustrated by leading contract development and manufacturing organizations broadening their capacities for high-content screening. For instance, Samsung Biologics reported in December 2025 that it strategically expanded its portfolio by introducing a dedicated organoid service in June 2025, aimed at improving clinical research flexibility and speed for its international clients.

Simultaneously, the application of rapid ATP testing within medical device reprocessing protocols is transforming hygiene compliance in healthcare settings. Faced with increasing pressure to reduce environmental impact and costs, hospitals are rapidly scaling their use of reprocessed single-use devices, a practice that demands strict cleaning verification prior to sterilization to avert infection transmission. This operational expansion directly fuels the use of ATP bioluminescence tests as a primary quality control standard. According to an April 2025 survey by the Association of Medical Device Reprocessors, U.S. hospitals realized over $451 million in savings in 2024 by utilizing regulated reprocessed devices, highlighting the massive inventory volume that now necessitates standardized validation of cleanliness.

Key Market Players

• Thermo Fisher Scientific Inc.
• Promega Corporation
• PerkinElmer Inc.
• Becton, Dickinson and Company (BD)
• Lonza Group AG
• DH Life Sciences, LLC.
• Abcam Limited
• Quest Diagnostics Incorporated
• BIOMeRIEUX S.A.
• 3M Company

Report Scope

In this report, the Global ATP Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

ATP Assays Market, By Type

• Luminometric ATP Assays
• Enzymatic ATP Assays
• Bioluminescence Resonance Energy Transfer (BRET) ATP Assays
• Cell-based ATP Assays
• Others

ATP Assays Market, By Application

• Drug Discovery and Development
• Clinical Diagnostics
• Environmental Testing
• Food Safety and Quality Testing
• Others

ATP Assays Market, By End Use

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Hospital and Diagnostics Laboratories

ATP Assays Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global ATP Assays Market.

Available Customizations:

Global ATP Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global ATP Assays Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Luminometric ATP Assays, Enzymatic ATP Assays, Bioluminescence Resonance Energy Transfer (BRET) ATP Assays, Cell-based ATP Assays, Others)
  • 5.2.2. By Application (Drug Discovery and Development, Clinical Diagnostics, Environmental Testing, Food Safety and Quality Testing, Others)
  • 5.2.3. By End Use (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospital and Diagnostics Laboratories)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America ATP Assays Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States ATP Assays Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada ATP Assays Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico ATP Assays Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End Use

7. Europe ATP Assays Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany ATP Assays Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End Use
  • 7.3.2. France ATP Assays Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom ATP Assays Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy ATP Assays Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain ATP Assays Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End Use

8. Asia Pacific ATP Assays Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China ATP Assays Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End Use
  • 8.3.2. India ATP Assays Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan ATP Assays Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea ATP Assays Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia ATP Assays Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End Use

9. Middle East & Africa ATP Assays Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia ATP Assays Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE ATP Assays Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa ATP Assays Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End Use

10. South America ATP Assays Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil ATP Assays Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia ATP Assays Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina ATP Assays Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global ATP Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Promega Corporation
• 15.3. PerkinElmer Inc.
• 15.4. Becton, Dickinson and Company (BD)
• 15.5. Lonza Group AG
• 15.6. DH Life Sciences, LLC.
• 15.7. Abcam Limited
• 15.8. Quest Diagnostics Incorporated
• 15.9. BIOMeRIEUX S.A.
• 15.10. 3M Company

16. Strategic Recommendations

17. About Us & Disclaimer